Chan, 2005, Epidemiology and reporting of randomised trials published in PubMed journals, Lancet, 365, 1159, 10.1016/S0140-6736(05)71879-1
Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, 449, 10.1016/S0140-6736(08)61039-9
Korhonen, 2012, Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma, J Biopharm Stat, 22, 1258, 10.1080/10543406.2011.592233
Smith, 2013, Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial, JAMA, 309, 1359, 10.1001/jama.2013.2813
Rimawi, 2012, Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?, J Clin Oncol, 10.1200/JCO.2010.34.2808
Brown, 2006, The stepped wedge trial design: a systematic review, BMC Med Res Methodol, 6, 54, 10.1186/1471-2288-6-54
Flaherty, 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N Engl J Med, 367, 1694, 10.1056/NEJMoa1210093
Djulbegovic, 2008, Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006, Arch Intern Med, 168, 632, 10.1001/archinte.168.6.632
Dighiero, 1998, Chlorambucil in indolent chronic lymphocytic leukemia, N Engl J Med, 338, 1506, 10.1056/NEJM199805213382104
Mateos, 2013, Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma, N Engl J Med, 369, 438, 10.1056/NEJMoa1300439
Kluin-Nelemans, 2012, Treatment of older patients with mantle-cell lymphoma, N Engl J Med, 367, 520, 10.1056/NEJMoa1200920
Amiri-Kordestani, 2012, Why do phase III clinical trials in oncology fail so often?, J Natl Cancer Inst, 104, 568, 10.1093/jnci/djs180